These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Apr 28, 2014Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer ImmunotherapiesAgenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United...
Apr 16, 2014
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014....
Mar 26, 2014
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus’ checkpoint modulator portfolio and immuno-oncology...
Mar 20, 2014GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-small Cell Lung Cancer Misses First Co-primary EndpointsGSK to continue study until third co-primary endpoint is assessed
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in...
Mar 5, 2014Agenus to host conference call beginning at 11 a.m. ET today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock...